Microbiome therapeutics could be the next big thing in pharma</strong></a><strong> | June 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.healthcare-brew.com/" target="_blank">Healthcare Brew</a><br /> The microbiome-based therapeutic market is expected to be worth $1.6 billion by 2026. Interest in this field is growing, especially with two drugs targeting the microbiome being approved in the past year. What is the outlook for the microbiome?</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/6a765e4c0d804586a4102e3227660788.ashx">Nine for 2023, part one: a reflection on inflection</strong></a><strong> | January 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> The first in a 3-part series on what trends will be affecting the pharma and life sciences industries in the upcoming year. This first part focuses on global healthcare environmental challenges and what they mean for the pharmaceutical industry.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/dbe44b6426d844aeb55c46450cde4a5a.ashx">Nine for 2023, part two: healthcare&rsquo;s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms</strong></a><strong> | January 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> This second part of the 3-part series focuses on opportunities for pharma; the unmet need which lies at the heart of better healthcare provision, Point of Care Diagnostics and new pharmacotherapy classes becoming commercially available in 2023.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/5b421c7a8561493a9c43f7dfcb84bc07.ashx">Nine for 2023, part three: surviving or thriving?</strong></a><strong> | January 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> This final part of the 3-part series concerns issues that will change the direction of healthcare and the pharmaceutical industry this year, with three key competitive issues for pharmaceutical companies in 2023 being assessed.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/2680731baf78447b944295d00dc7a77f.ashx">3 ways healthcare systems can reduce their carbon footprint</strong></a><strong> | November 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> Rapid climate change has a direct impact on human health. The risk to human health bears down heavily upon healthcare systems. What can be done by these systems to reduce their carbon emissions?</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/33cd80cb8e4940dca84807830911ab39.ashx">&ldquo;Your order has been dispatched&rdquo;: Moving patient care closer to the home</strong></a><strong> | October 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://medhealthoutlook.com/" target="_blank">Medhealth Outlook</a><br /> Healthcare has increasingly moved towards treating patients at an individual level. As part of this phenomena there is a growing focus on providing patients greater flexibility on the location and timing of how they receive care. Learn how pharma and others can success during this change.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/6cff485c798644d1a0228ec9e0a44082.ashx">Is the launch environment really more competitive now?</strong></a><strong> | October 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> It&rsquo;s often stated - mostly without reference to data - that the environment for innovative launches is more competitive now than it ever has been. Is this true? We interrogate this claim using IQVIA&rsquo;s long term market data to analyse nearly 30 years of launches.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/de00d1622aba4ecf8df8bcfec48d018c.ashx">How can countries achieve digital maturity in healthcare?</strong></a><strong> | August 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> Healthcare systems are becoming increasingly digitised, but this trend has accelerated in the last 10 years, as well as been given a huge boost by the COVID-19 pandemic. Progression towards digital maturity is uneven between countries, but there are successful examples to follow.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/4cc5453e53f1430abc834161eaebfd10.ashx">How clinical development can tackle Africa's unique health needs</strong></a><strong> | May 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> By 2050, the United Nations projects that 25% of all humanity will be African, with non-communicable diseases poised to become the leading cause of deaths in sub-Saharan Africa. The poor level of commercially led clinical development activity in Africa must be addressed considering these changing factors.</p>" /> Microbiome therapeutics could be the next big thing in pharma</strong></a><strong> | June 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.healthcare-brew.com/" target="_blank">Healthcare Brew</a><br /> The microbiome-based therapeutic market is expected to be worth $1.6 billion by 2026. Interest in this field is growing, especially with two drugs targeting the microbiome being approved in the past year. What is the outlook for the microbiome?</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/6a765e4c0d804586a4102e3227660788.ashx">Nine for 2023, part one: a reflection on inflection</strong></a><strong> | January 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> The first in a 3-part series on what trends will be affecting the pharma and life sciences industries in the upcoming year. This first part focuses on global healthcare environmental challenges and what they mean for the pharmaceutical industry.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/dbe44b6426d844aeb55c46450cde4a5a.ashx">Nine for 2023, part two: healthcare&rsquo;s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms</strong></a><strong> | January 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> This second part of the 3-part series focuses on opportunities for pharma; the unmet need which lies at the heart of better healthcare provision, Point of Care Diagnostics and new pharmacotherapy classes becoming commercially available in 2023.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/5b421c7a8561493a9c43f7dfcb84bc07.ashx">Nine for 2023, part three: surviving or thriving?</strong></a><strong> | January 2023</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> This final part of the 3-part series concerns issues that will change the direction of healthcare and the pharmaceutical industry this year, with three key competitive issues for pharmaceutical companies in 2023 being assessed.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/2680731baf78447b944295d00dc7a77f.ashx">3 ways healthcare systems can reduce their carbon footprint</strong></a><strong> | November 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> Rapid climate change has a direct impact on human health. The risk to human health bears down heavily upon healthcare systems. What can be done by these systems to reduce their carbon emissions?</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/33cd80cb8e4940dca84807830911ab39.ashx">&ldquo;Your order has been dispatched&rdquo;: Moving patient care closer to the home</strong></a><strong> | October 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://medhealthoutlook.com/" target="_blank">Medhealth Outlook</a><br /> Healthcare has increasingly moved towards treating patients at an individual level. As part of this phenomena there is a growing focus on providing patients greater flexibility on the location and timing of how they receive care. Learn how pharma and others can success during this change.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/6cff485c798644d1a0228ec9e0a44082.ashx">Is the launch environment really more competitive now?</strong></a><strong> | October 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://pharmaphorum.com/" target="_blank">Pharmaphorum</a><br /> It&rsquo;s often stated - mostly without reference to data - that the environment for innovative launches is more competitive now than it ever has been. Is this true? We interrogate this claim using IQVIA&rsquo;s long term market data to analyse nearly 30 years of launches.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/de00d1622aba4ecf8df8bcfec48d018c.ashx">How can countries achieve digital maturity in healthcare?</strong></a><strong> | August 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> Healthcare systems are becoming increasingly digitised, but this trend has accelerated in the last 10 years, as well as been given a huge boost by the COVID-19 pandemic. Progression towards digital maturity is uneven between countries, but there are successful examples to follow.</p> <p>&nbsp;</p> <p><a href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"-/media/4cc5453e53f1430abc834161eaebfd10.ashx">How clinical development can tackle Africa's unique health needs</strong></a><strong> | May 2022</strong><br /> Source: <a rel="noopener noreferrer" href=https://www.iqvia.com/locations/emea/emea-thought-leadership/emea-insights/"https://www.weforum.org/" target="_blank">World Economic Forum</a><br /> By 2050, the United Nations projects that 25% of all humanity will be African, with non-communicable diseases poised to become the leading cause of deaths in sub-Saharan Africa. The poor level of commercially led clinical development activity in Africa must be addressed considering these changing factors.</p>" />
Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Integrated Global Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

IQVIA TECHNOLOGIES

"Harness technology for a healthier world.

EXPLORE MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety and quality.

COMPLIANCE OVERVIEW
Integrated Global Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2023

READ MORE

Webinar

"Global Consumer Health Trends 2023 Webinar Series

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • Connected Intelligence
  • AI & Machine Learning
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Genomics
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
AI & Machine Learning with a healthcare IQ.

Artificial intelligence is accelerating opportunities. Realizing the benefits for healthcare requires the right expertise. Together, we can solve the problems of today, and drive the breakthroughs of tomorrow.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
Unlock the power of genomic research.

IQVIA enables genomic research via global access to a network of genomic-clinical data, proprietary technologies that enable federated analytics, and therapeutic area & bioinformatics expertise to help you answer your most pressing research questions.

LEARN MORE
MAIN/Careers
Careers/
WORKING AT IQVIA

Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.

LEARN MORE
LIFE AT IQVIA

Careers, culture and everything in between. Find out what’s going on right here, right now.

LEARN MORE

WE’RE HIRING

"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.

SEARCH JOBS
MAIN/Contact Us
Contact Us/

EMEA Thought Leadership

Articles in the trade press

Microbiome therapeutics could be the next big thing in pharma | June 2023
Source: Healthcare Brew
The microbiome-based therapeutic market is expected to be worth $1.6 billion by 2026. Interest in this field is growing, especially with two drugs targeting the microbiome being approved in the past year. What is the outlook for the microbiome?

 

Nine for 2023, part one: a reflection on inflection | January 2023
Source: Pharmaphorum
The first in a 3-part series on what trends will be affecting the pharma and life sciences industries in the upcoming year. This first part focuses on global healthcare environmental challenges and what they mean for the pharmaceutical industry.

 

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms | January 2023
Source: Pharmaphorum
This second part of the 3-part series focuses on opportunities for pharma; the unmet need which lies at the heart of better healthcare provision, Point of Care Diagnostics and new pharmacotherapy classes becoming commercially available in 2023.

 

Nine for 2023, part three: surviving or thriving? | January 2023
Source: Pharmaphorum
This final part of the 3-part series concerns issues that will change the direction of healthcare and the pharmaceutical industry this year, with three key competitive issues for pharmaceutical companies in 2023 being assessed.

 

3 ways healthcare systems can reduce their carbon footprint | November 2022
Source: World Economic Forum
Rapid climate change has a direct impact on human health. The risk to human health bears down heavily upon healthcare systems. What can be done by these systems to reduce their carbon emissions?

 

“Your order has been dispatched”: Moving patient care closer to the home | October 2022
Source: Medhealth Outlook
Healthcare has increasingly moved towards treating patients at an individual level. As part of this phenomena there is a growing focus on providing patients greater flexibility on the location and timing of how they receive care. Learn how pharma and others can success during this change.

 

Is the launch environment really more competitive now? | October 2022
Source: Pharmaphorum
It’s often stated - mostly without reference to data - that the environment for innovative launches is more competitive now than it ever has been. Is this true? We interrogate this claim using IQVIA’s long term market data to analyse nearly 30 years of launches.

 

How can countries achieve digital maturity in healthcare? | August 2022
Source: World Economic Forum
Healthcare systems are becoming increasingly digitised, but this trend has accelerated in the last 10 years, as well as been given a huge boost by the COVID-19 pandemic. Progression towards digital maturity is uneven between countries, but there are successful examples to follow.

 

How clinical development can tackle Africa's unique health needs | May 2022
Source: World Economic Forum
By 2050, the United Nations projects that 25% of all humanity will be African, with non-communicable diseases poised to become the leading cause of deaths in sub-Saharan Africa. The poor level of commercially led clinical development activity in Africa must be addressed considering these changing factors.

Contact Us